Large biotechs doing better than big drugmakers, report finds

04/19/2013 | BioPharm International

Big biotech firms have beaten major drugmakers since 2010 in terms of sales growth, income, research investment and market capitalization, better placing them to deal with a changing market, according to a report from Burrill & Co. Big biotech's market cap grew 57%, to $260.6 billion, from Jan. 1, 2010, to Dec. 31, 2012, compared with a 17% hike, to $1.257 billion, for major drugmakers. "The big jump in the value of Big Biotech companies is not just a matter of investor speculation," G. Steven Burrill said. "These companies have had significant clinical and market successes that have driven their values higher."

View Full Article in:

BioPharm International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA